Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: Long-term results

Bone Marrow Transplantation

Volumn 47, Issue 7, 2012, Pages 946-951

  Bowen, J D ^a   Kraft, G H ^b   Wundes, A ^c   Guan, Q ^b   Maravilla, K R ^b   Gooley, T A ^c,d   McSweeney, P A ^e   Pavletic, S Z ^f   Openshaw, H ^c   Storb, R ^c,d   Wener, M ^b   McLaughlin, B A ^d   Henstorf, G R ^d   Nash, R A ^c,d  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e National Cancer Institute ^*  (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CY; hematopoietic cell transplantation; multiple sclerosis; oligoclonal bands; TBI

Indexed keywords

CYCLOPHOSPHAMIDE; OLIGOCLONAL BAND; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TREATMENT FAILURE; WHOLE BODY RADIATION;

ADULT; ANTILYMPHOCYTE SERUM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84863727030     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.208     Document Type: Article

References (42)

1. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
2. Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L et al. The challenge of follow-on biologics for treatment of multiple sclerosis (Review). Neurology 2009; 73: 552-559.
3. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigenspecific tolerance by syngeneic bone marrow transplantation. Mult Scler 1999; 5: 17-21
4. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396.
5. Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis [Erratum appears in Ann Rheum Dis. 2008 Feb;67(2):280]. Ann Rheum Dis 2008; 67: 98-104.
6. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
7. Brinkman DM, de Kleer IM, Ten Cate R, Van Rossum MA, Bekkering WP, Fasth A et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56: 2410-2421.
8. van Bekkum DW. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25: 357-364.
9. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park M-S et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364-2372.
10. Storek J, Zhao Z, Lin E, Berger T, McSweeney PA, Nash RA et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol 2004; 113: 285-298.
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (Usa) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46: 907-911.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Rowley SD, Loken M, Radich J, Kunkle LA, Mills BJ, Gooley T et al. Isolation of CD34+ cells from blood stem cell components using the Baxter isolex system. Bone Marrow Transplant 1998; 21: 1253-1262.
15. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865-870.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after highdose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583-591.
19. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147-2150.
20. Fassas A, Kimiskidis VK. Stem cell transplantation for multiple sclerosis: what is the evidence? (Review). Blood Rev 2003; 17: 233-240.
21. Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnostopoulos A, Tsimourtou V et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011; 76: 1066-1070.
22. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601-2607.
23. Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84: 276-281.
24. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008; 36: 922-928.
25. Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010; 16: 685-693.
26. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814-823.
27. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373-2378.
28. Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005; 11: 367-371.
29. Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009; 15: 229-237.
30. Kimiskidis V, Sakellari I, Tsimourtou V, Kapina V, Papagiannopoulos S, Kazis D et al. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler 2008; 14: 278-283.
31. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study [Erratum appears in Lancet Neurol. 2009 Apr;8(4):309]. Lancet Neurol 2009; 8: 244-253.
32. Obermeier B, Mentele R, Malotka J, Kellermann J, Kumpfel T, Wekerle H et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008; 14: 688-693.
33. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563-575.
34. Carreras E, Saiz A, Marin P, Martinez C, Rovira M, Villamor N et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306-314.
35. Mondria T, Lamers CH, te Boekhorst PA, Gratama JW, Hintzen RQ. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 1013-1015.
36. Portaccio E, Amato MP, Siracusa G, Pagliai F, Sorbi S, Guidi S et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler 2007; 13: 676-678.
37. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130: 1254-1262.
38. Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meche FG et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 46-50.
39. Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 2011; 17: 204-213.
40. Jager HR, Williams EJ, Savage DG, Rule SA, Hajnal JV, Sikora K et al. Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. Am J Neurorad 1996; 17: 1275-1282.
41. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006; 66: 1935-1937.
42. Roccatagliata L, Rocca M, Valsasina P, Bonzano L, Sormani M, Saccardi R et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 2007; 13: 1068-1070.